Home / Market News / $ACRS
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Wedbush Adjusts Aclaris Therapeutics Price Target to $8

Oct 29, 2026, 1:11 PM UTC · Primary ticker $ACRS

Wedbush Securities has lowered its price target for Aclaris Therapeutics from $10 to $8, while surprisingly maintaining an 'Outperform' rating. This adjustment reflects a revised valuation assessment by the analyst, indicating a potentially more cautious near-term outlook despite continued long-term optimism.

Wedbush Securities has adjusted its price target for Aclaris Therapeutics (ACRS) from $10 to $8. This action is significant because a price target reduction typically signals a more conservative outlook on a company's future performance or valuation, which can put downward pressure on the stock in the short term. However, the decision to maintain an 'Outperform' rating suggests that Wedbush still believes Aclaris will outperform the broader market, indicating a potential disconnect or a belief that the stock is undervalued even at the lower target. Traders should note the immediate negative sentiment from the price target cut, but also consider the analyst's continued positive long-term view as a potential opportunity if the market overreacts.

$ACRS negative Price target reduction
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.